Elicitation of Broadly Protective Antibodies following Infection with Influenza Viruses Expressing H1N1 Computationally Optimized Broadly Reactive Hemagglutinin Antigens.
Influenza viruses represent a threat to the world population. The currently available standard of care influenza vaccines are offered for each influenza season to prevent infection and spread of influenza viruses. Current vaccine formulations rely on using wild-type Ags, including the hemagglutinin (HA) and neuraminidase (NA) proteins as the primary immune targets of the vaccine. However, vaccine effectiveness varies from season to season, ranging from 10 to 75% depending on season and on age group studied. To improve rates of vaccine effectiveness, a new generation of computationally optimized broadly reactive Ags (COBRA)-based vaccines have been developed as a next-generation influenza vaccine. In this report, mice were intranasally, i.p., or i.m. primed with reassortant influenza viruses expressing different H1N1 COBRA HA proteins. These mice were subsequently boosted i.p. or i.m. with the same viruses. Sera collected from mice that were intranasally infected and i.p. boosted with COBRA-based viruses had broad anti-HA IgG binding, hemagglutination inhibition, and neutralizing activity against a panel of seasonal and pandemic H1N1 viruses. Mice immunized with viruses expressing a seasonal or pandemic H1N1 HA protein had antisera that recognized fewer viruses in the panel. Overall, COBRA-based HA proteins displayed on the surface of a virus elicited a breadth of Abs that recognized and neutralized historical H1N1 strains as well as more contemporary H1N1 viruses.